The COVID-19 pandemic has upended the way we live and work. But it is taking a much more significant toll on the lives of women around the world. Gender equality must be at the heart of not only our response, but our attempts to restructure systems to be fairer and more equal to recover better.

On 17 September on the sidelines of the 75th UN General Assembly, I was pleased to be part of the inaugural Women in Global Health Security Summit (also known as the COVID 50/50 Summit). It was an extraordinary virtual event which brought together women and men alike from across sectors, including global leaders like President Sahle-Work Zewde of Ethiopia, World Health Organization (WHO) Director-General Dr. Tedros Adhanom Ghebreyesus and Gavi’s Deputy CEO Anuradha Gupta. No matter who spoke it was resoundingly clear—we are far from our goals of achieving gender parity in any realm, but especially in the global health security space, and we all must commit to taking action now to do better if we want to build the stronger, more resilient health systems that we desperately need.

Gender equality must be at the heart of not only our response, but our attempts to restructure systems to be fairer and more equal to recover better.

As part of the Summit, more than 40 global organisations, including Gavi, made actionable pledges and commitments which will move us closer to removing barriers to realising gender transformed leadership as we aim to end the COVID-19 pandemic, and leave stronger global health security systems in its wake.  Some of these commitments came from governments, others came from major global health organisations like the Global Fund, Unitaid, and FIND, all of which are working with Gavi and other global partners on creating equitable access to COVID-19 tools through the ACT Accelerator and strengthening health infrastructure in the process. But organisations, governments and even individual citizens will need to take a truly transformative approach to addressing barriers to gender equality, including in leadership roles, if we want to ensure our response doesn’t further erode progress as we seek to build back better from this pandemic.

As Dr. Roopa Dhatt, Executive Director and Co-Founder of Women in Global Health said during the Summit, “At Women in Global Health, our mantra is that global health security rests on women. While women provide US$ 3 trillion of care annually, half of that is currently unpaid in informal systems. We are asking for a new social contract for women in health that recognises and values their contribution.”

This new social contract will be imperative if we want to not only end the global COVID-19 pandemic, but also if we want to make good on the promise of creating health and well-being for all under the Sustainable Development Goals.

Gender-transformative leadership can look like many things. It can be infrastructure that enables women to attend schools and contribute to the workforce by taking care of childcare or elder care needs. It can be disaggregating data by gender and other factors to better understand and re-engineer the effects of the pandemic and corresponding fiscal stimulus or social protection policies. When we don’t take gender into account, we risk stalling sustainable solutions to the COVID-19 pandemic and its economic and societal fallouts and remaining woefully underprepared to future threats that undoubtedly lay ahead.

The commitments made during the COVID 50/50 Summit were just the start. Now is the time to get to work and put these promises into action and bring others along as we try to transform the global health security landscape. The future we have promised to deliver depends on it.

To learn more about the COVID 50/50 initiative, visit

About the author

Moses John Bockarie  

Kate Dodson is the Vice President for Global Health at the United Nations Foundation. She is also a board member of Women in Global Health. 

We'd love to hear your feedback!

Related content

CEPI spoke with vaccine safety expert, Dr Robert Chen, Science Director of The Brighton Collaboration – the largest global organisation of scientific experts on vaccine safety – about how vaccine safety is assessed in clinical trials and how…

Interim analysis of the AstraZeneca/Oxford COVID-19 vaccine candidate – to which Gavi has secured access – suggests an efficacy of 62– 90%. Crucially, the vaccine can be administered and distributed using existing health care and supply chain…

How will the COVAX Facility ensure equitable access to COVID-19 vaccines is indeed equitable? By Aurélia Nguyen, Managing Director, Office of the COVAX Facility

An interim analysis of the Pfizer/BioNTech vaccine candidate suggests is more efficacious than many had dared to expect. The announcement is a welcome indication that a safe and effective COVID-19 vaccine might be within reach, but there are…

Never has the development of vaccines been so widely anticipated as for COVID-19, and arguably never has so much been at stake. Because without COVID-19 vaccines, we cannot bring this crisis to a swift end.

Mathematical modelling suggests that if wealthy countries stockpile COVID-19 vaccines, we will see nearly twice as many deaths than if vaccines were shared equally across the globe.

CEPI’s strategic investments in vaccine manufacturing at facilities around the world will support the COVAX goal to produce 2 billion doses of safe and effective vaccine by the end of 2021.

President of Niger H.E. Issoufou Mahamadou talks about the importance of routine immunisation and Gavi support in Niger, and the need for ensuring universal access to COVID-19 vaccines through the COVAX Facility.

Most vaccine candidates in early development fail: this is the stark reality of vaccine development.

Gavi’s CEO explains how its Advance Market Commitment mechanism will make COVID-19 vaccines available to lower-income countries.

The UK is expected to host the world’s first COVID-19 human “challenge” trials, which will involve deliberately infecting healthy volunteers with coronavirus to assess the effectiveness of experimental vaccines. So far, around 2,000 potential…

When I join Gavi in January, it will be at a time when it is contemplating the most ambitious period in its history.

No one is safe until everyone is safe. This phrase has become a slogan for global health figures but what does it mean in the worldwide COVID-19 response?

As CEO of Gavi, the Vaccine Alliance funded largely by Bill Gates, Dr Seth Berkley has helped vaccinate almost half the world’s children from fatal and debilitating diseases. His current baby is the COVAX Facility to help develop, manufacture and…

3 September 2020

COVAX explained

To end this global health crisis we don’t just need COVID-19 vaccines, we also need to ensure that everyone in the world has access to them.

When COVID-19 vaccines become available demand is likely to outstrip supply, at least initially. So, who should be first in line?

Briefings led by Gavi, CEPI and WHO over the past two weeks saw participation from at least 136 countries interested in joining a COVAX Facility aimed at guaranteeing equitable access to eventual COVID-19 vaccines.

With more than 200 COVID-19 vaccines already in development, why do we need the Access to COVID-19 Tools Accelerator Vaccine Pillar, or COVAX Pillar?

With so many COVID-19 candidate vaccines in development, and with most of them likely to fail, what’s the best way for governments to ensure they back a winner and ensure there are enough doses for everyone?

Subscribe to our newsletter